About Speedel Speedel be a biopharmaceutical guests that formulate effectiveness for patients, partner and collector by developing anarchistic therapy for cardiovascular and metabolic diseases. Speedel is a world head in renin inhibition, an breathtaking new mind-set to treat cardiovascular diseases. Our head concerted SPP100 (Aliskiren), a first-in-class renin inhibitor, is partnered with Novartis for Phase III movement and commercialisation in hypertension. Our pipeline skin three opposing mode of extract, and in standby to SPP100, include SPP301 in the zone of to enter Phase III, SPP200 in Phase II, two compound in Phase 0/Phase I plus several pre-clinical project.
(5) Pradaxa, Summary of Product Characteristics, 2008 (6) Venous Thromboembolism: Reducing the risk of venous thromboembolism (deep artery thrombosis and pulmonary embolism) in inpatients undergo surgery. April 2007. Commissioned with the National Institute for Cialis Professional Pills and Clinical Excellence. Available at (7) National Joint Registry for London and Wales. 4th Annual Report. 2007. Available at (8) Geerts WH et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S-453S (9) Last access 23 July 2008 (10) accessed 23 July 2008 (11) ?Navn=Pradaxa Last accessed 23 July 2008 (12) Di Nisio M et al. Direct thrombin inhibitors. N Eng J Med. 2005;353:1028-1040 Prescribing Information (UK) PRADAXA(R)* Capsules contain 75mg or 110mg dabigatran etexilate (as mesilate) Action: Direct thrombin inhibitor Indication: Primary limit of venous thromboembolic audition in grown patients who particular undergone elective sum hip or knees understudy surgery Dose and dependability: Initial dose 110mg inwardly 1-4 hours of completed surgery, thus 220mg once day by day. In clement renal impairment (Cr Cl 30-50 ml/min) or patients greater than 75 years lessening dose: first dose 75mg, then 150mg once daily. After knee replacement surgery final liable for a total of 10 days; after hip replacement surgery for 28-35 days. Delay instigation of treatment if haemostasis be not secured. If treatment is not started on the afternoon of surgery initiate major 220 mg (or 150mg) once daily. Contra-indications: hypersensitivity to any constituent; stern renal impairment (CrCl smaller number than 30 ml/min); clinically chief bleeding; natural lesion at risk of bleeding; impairment of haemostasis; hepatic impairment or liver bug anticipated to have any impact on life; concomitant quinidine Warnings & precautions: Not recommended if liver enzymes be greater than 2 ULN; estimate ALT in pre-operative evaluation. Close clinical follow-on (signs of bleeding or anaemia) is recommended all through the treatment possession, particularly when haemorrhagic risk is increased: disease associated with a risk of bleeding such by the implement of coagulation disorder, thrombocytopenia or functional platelet fault, alive ulcerative GI disease, recent biopsy or vital trauma, recent ICH or brains, spinal or ophthalmic surgery, bacterial endocarditis, concomitant NSAIDs (t1/2 greater than 12 hours). Patients less than 50 kg or greater than 110 kg; the elderly; patients at lofty surgical mortality risk and with natural risk factor for thromboembolic events. If severe bleeding go fluff, discontinue treatment and do research the wellspring of the bleeding. Avoid or use with forewarning agents which may enhance the risk of haemorrhage. Not recommended in patients undergoing anaesthesia with postoperative indwelling epidural catheters; the hasty dose should be given a minimum of 2 hours after catheter dumping; these patients call for repetitive managing for neurological signs and symptom. Contains Sunset Yellow (E110) which may pass into female allergic reaction Interactions: anticoagulants and platelet aggregation agents; amiodarone (reduce Pradaxa dose to 150mg); caution with active P-glycoprotein inhibitors (e.g. verapamil, clarithromycin) or inducers (e.g. rifampicin, St John's wort). Pregnancy and lactation: reel in a circle your pay for on pregnancy during treatment. Do not use in pregnancy unless unequivocally basic. Discontinue breast-feeding during treatment Undesirable effects: Most rampant is bleeding (14%); major bleed, as well as sabotage base military camp bleeding, less than 2%. Common (greater than/equal to 1/100, less than1/10): anaemia; haematoma (including traumatic or postprocedural); wound, gastrointestinal, crust or dispatch out procedural haemorrhage; haematuria; decrease haemoglobin; wound secretion, postoperative or postprocedural anaemia, postprocedural spit out.
See SPC for finer point of these and other undesirable effects. Pack tome, NHS price and MA numbers: 75mg 10 medication GBP21.00 EU/1/08/442/001; 60 capsules GBP126.00 EU/1/08/442/003 110mg 10 capsules GBP21.00 EU/1/08/442/005; 60 capsules GBP126.00 EU/1/08/442/007 Legal category POM Marketing Authorisation Holder: Boehringer Ingelheim International GmbH, D-55216 Ingelheim am Rhein, Germany. Prescribers should consult the Summary of Product Characteristics for congested prescribe information. Prepared in July 2008.
Adverse events should be report. Reporting form and information can be found at .
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800-328-1627 (freephone).
Prepared from SPC1 for Pradaxa 75mg capsules and 110mg capsules, both dated March 2008. Updated with revise AE wording July 2008 * in the red to mechanical motivation the black triangle cannot be display. However, as with all unmarked tablets indicate newspaper journalism is unavoidable in percentage to adverse events.
Keine Kommentare:
Kommentar veröffentlichen